Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Autor:	Sandy W. Wong, Noffar Bar, Laura Paris, Craig C Hofmeister, Markus Hansson, Armando Santoro, Maria-Victoria Mateos, Paula Rodríguez-Otero, Johan Lund, Cristina Encinas, Andrew J. Yee, Albert Oriol, Claudio Cerchione, Javier de la Rubia, Barbara Ferstl, Kristina Carlson, Paz Ribas, Arancha Bermúdez, Isaac W. Boss, Allison Gaudy, Shaoyi Li, Kevin Hsu, Colin D. Godwin, Michael R. Burgess, Jesús San-Miguel, Luciano J. Costa
Rok vydání:	2022
Předmět:	Immunology Cell Biology Hematology Biochemistry
Zdroj:	Blood. 140:400-402
ISSN:	1528-0020 0006-4971
DOI:	10.1182/blood-2022-159009
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::0afc08455bdb57f4f185504c94b848b7 https://doi.org/10.1182/blood-2022-159009 Zobrazit plný text záznamu